AAPL313.39+2.73 (+0.88%) ▲|ABBV252.74-1.91 (-0.75%) ▼|ABT95.18-0.66 (-0.69%) ▼|ACN137.19-4.95 (-3.48%) ▼|ADBE220.94-0.60 (-0.27%) ▼|AMAT570.50+16.00 (+2.89%) ▲|AMD517.41+1.30 (+0.25%) ▲|AMGN367.99-0.11 (-0.03%) ▼|AMT165.04-0.21 (-0.13%) ▼|AMZN243.62-2.36 (-0.96%) ▼|AVGO388.69+17.91 (+4.83%) ▲|AXP336.39-13.19 (-3.77%) ▼|BA224.95-6.73 (-2.90%) ▼|BAC58.30-1.56 (-2.61%) ▼|BKNG174.29-7.66 (-4.21%) ▼|BLK990.34-19.09 (-1.89%) ▼|BMY57.54-0.43 (-0.74%) ▼|BNY150.14-2.77 (-1.81%) ▼|BRK-B494.79-9.21 (-1.83%) ▼|C137.39-3.38 (-2.40%) ▼|CAT948.08+7.96 (+0.85%) ▲|CL93.04-1.99 (-2.09%) ▼|CMCSA23.19-0.22 (-0.94%) ▼|COF191.95-10.94 (-5.39%) ▼|COP110.72+2.28 (+2.10%) ▲|COST953.13+5.63 (+0.59%) ▲|CRM166.58-2.94 (-1.73%) ▼|CSCO113.82+2.03 (+1.82%) ▲|CVS104.47+0.14 (+0.13%) ▲|CVX175.97+1.96 (+1.13%) ▲|DE596.74-6.87 (-1.14%) ▼|DHR190.77-3.42 (-1.76%) ▼|DIS96.70-0.78 (-0.80%) ▼|DUK126.79-1.43 (-1.12%) ▼|EMR136.48-1.43 (-1.04%) ▼|FDX309.76-3.12 (-1.00%) ▼|GD374.31-0.33 (-0.09%) ▼|GE356.03-10.95 (-2.98%) ▼|GEV1,070.99-6.09 (-0.57%) ▼|GILD135.82-0.54 (-0.40%) ▼|GM76.24+0.21 (+0.28%) ▲|GOOG358.71-4.91 (-1.35%) ▼|GOOGL361.92-5.11 (-1.39%) ▼|GS1,029.64-13.34 (-1.28%) ▼|HD336.21-9.00 (-2.61%) ▼|HON220.36-4.69 (-2.08%) ▼|IBM302.05-4.08 (-1.33%) ▼|INTC110.24-0.15 (-0.14%) ▼|INTU272.10-9.07 (-3.23%) ▼|ISRG415.10-12.20 (-2.86%) ▼|JNJ263.40-3.84 (-1.44%) ▼|JPM330.62-8.60 (-2.54%) ▼|KO83.40-0.65 (-0.77%) ▼|LIN527.67-10.56 (-1.96%) ▼|LLY1,215.83-19.73 (-1.60%) ▼|LMT527.96-7.42 (-1.39%) ▼|LOW212.85-8.05 (-3.64%) ▼|LRCX333.15+7.02 (+2.15%) ▲|MA519.86-11.76 (-2.21%) ▼|MCD278.25-3.96 (-1.40%) ▼|MDLZ59.48-0.74 (-1.23%) ▼|MDT82.01-1.82 (-2.17%) ▼|META603.12-12.46 (-2.02%) ▼|MMM154.70-3.31 (-2.09%) ▼|MO72.81-0.15 (-0.21%) ▼|MRK125.99-2.87 (-2.23%) ▼|MS218.07-3.97 (-1.79%) ▼|MSFT383.34-5.50 (-1.41%) ▼|MU948.80+10.42 (+1.11%) ▲|NEE87.44-1.03 (-1.16%) ▼|NFLX75.59-0.59 (-0.77%) ▼|NKE42.89-0.32 (-0.74%) ▼|NOW107.78-2.95 (-2.66%) ▼|NVDA204.12+7.19 (+3.65%) ▲|ORCL140.49-1.11 (-0.78%) ▼|PEP142.51-2.47 (-1.70%) ▼|PFE24.05-0.02 (-0.08%) ▼|PG148.40-4.35 (-2.85%) ▼|PLTR132.22-2.15 (-1.60%) ▼|PM187.07-0.72 (-0.38%) ▼|QCOM186.56+3.59 (+1.96%) ▲|RTX194.91-5.94 (-2.96%) ▼|SBUX103.87+0.26 (+0.25%) ▲|SCHW101.70-0.23 (-0.23%) ▼|SO96.38-0.91 (-0.94%) ▼|SPG219.09-8.10 (-3.57%) ▼|T21.12+0.03 (+0.14%) ▲|TMO510.13-6.49 (-1.26%) ▼|TMUS180.14-4.59 (-2.48%) ▼|TSLA394.06-8.84 (-2.19%) ▼|TXN301.32+8.02 (+2.73%) ▲|UBER73.60-0.73 (-0.98%) ▼|UNH425.60-2.59 (-0.60%) ▼|UNP280.94-2.18 (-0.77%) ▼|UPS109.94-2.02 (-1.80%) ▼|USB61.00-1.89 (-3.01%) ▼|V347.53-4.67 (-1.33%) ▼|VZ42.45-0.14 (-0.33%) ▼|WFC85.56-1.62 (-1.86%) ▼|WMT113.10+1.56 (+1.40%) ▲|XOM141.13-0.56 (-0.40%) ▼|AAPL313.39+2.73 (+0.88%) ▲|ABBV252.74-1.91 (-0.75%) ▼|ABT95.18-0.66 (-0.69%) ▼|ACN137.19-4.95 (-3.48%) ▼|ADBE220.94-0.60 (-0.27%) ▼|AMAT570.50+16.00 (+2.89%) ▲|AMD517.41+1.30 (+0.25%) ▲|AMGN367.99-0.11 (-0.03%) ▼|AMT165.04-0.21 (-0.13%) ▼|AMZN243.62-2.36 (-0.96%) ▼|AVGO388.69+17.91 (+4.83%) ▲|AXP336.39-13.19 (-3.77%) ▼|BA224.95-6.73 (-2.90%) ▼|BAC58.30-1.56 (-2.61%) ▼|BKNG174.29-7.66 (-4.21%) ▼|BLK990.34-19.09 (-1.89%) ▼|BMY57.54-0.43 (-0.74%) ▼|BNY150.14-2.77 (-1.81%) ▼|BRK-B494.79-9.21 (-1.83%) ▼|C137.39-3.38 (-2.40%) ▼|CAT948.08+7.96 (+0.85%) ▲|CL93.04-1.99 (-2.09%) ▼|CMCSA23.19-0.22 (-0.94%) ▼|COF191.95-10.94 (-5.39%) ▼|COP110.72+2.28 (+2.10%) ▲|COST953.13+5.63 (+0.59%) ▲|CRM166.58-2.94 (-1.73%) ▼|CSCO113.82+2.03 (+1.82%) ▲|CVS104.47+0.14 (+0.13%) ▲|CVX175.97+1.96 (+1.13%) ▲|DE596.74-6.87 (-1.14%) ▼|DHR190.77-3.42 (-1.76%) ▼|DIS96.70-0.78 (-0.80%) ▼|DUK126.79-1.43 (-1.12%) ▼|EMR136.48-1.43 (-1.04%) ▼|FDX309.76-3.12 (-1.00%) ▼|GD374.31-0.33 (-0.09%) ▼|GE356.03-10.95 (-2.98%) ▼|GEV1,070.99-6.09 (-0.57%) ▼|GILD135.82-0.54 (-0.40%) ▼|GM76.24+0.21 (+0.28%) ▲|GOOG358.71-4.91 (-1.35%) ▼|GOOGL361.92-5.11 (-1.39%) ▼|GS1,029.64-13.34 (-1.28%) ▼|HD336.21-9.00 (-2.61%) ▼|HON220.36-4.69 (-2.08%) ▼|IBM302.05-4.08 (-1.33%) ▼|INTC110.24-0.15 (-0.14%) ▼|INTU272.10-9.07 (-3.23%) ▼|ISRG415.10-12.20 (-2.86%) ▼|JNJ263.40-3.84 (-1.44%) ▼|JPM330.62-8.60 (-2.54%) ▼|KO83.40-0.65 (-0.77%) ▼|LIN527.67-10.56 (-1.96%) ▼|LLY1,215.83-19.73 (-1.60%) ▼|LMT527.96-7.42 (-1.39%) ▼|LOW212.85-8.05 (-3.64%) ▼|LRCX333.15+7.02 (+2.15%) ▲|MA519.86-11.76 (-2.21%) ▼|MCD278.25-3.96 (-1.40%) ▼|MDLZ59.48-0.74 (-1.23%) ▼|MDT82.01-1.82 (-2.17%) ▼|META603.12-12.46 (-2.02%) ▼|MMM154.70-3.31 (-2.09%) ▼|MO72.81-0.15 (-0.21%) ▼|MRK125.99-2.87 (-2.23%) ▼|MS218.07-3.97 (-1.79%) ▼|MSFT383.34-5.50 (-1.41%) ▼|MU948.80+10.42 (+1.11%) ▲|NEE87.44-1.03 (-1.16%) ▼|NFLX75.59-0.59 (-0.77%) ▼|NKE42.89-0.32 (-0.74%) ▼|NOW107.78-2.95 (-2.66%) ▼|NVDA204.12+7.19 (+3.65%) ▲|ORCL140.49-1.11 (-0.78%) ▼|PEP142.51-2.47 (-1.70%) ▼|PFE24.05-0.02 (-0.08%) ▼|PG148.40-4.35 (-2.85%) ▼|PLTR132.22-2.15 (-1.60%) ▼|PM187.07-0.72 (-0.38%) ▼|QCOM186.56+3.59 (+1.96%) ▲|RTX194.91-5.94 (-2.96%) ▼|SBUX103.87+0.26 (+0.25%) ▲|SCHW101.70-0.23 (-0.23%) ▼|SO96.38-0.91 (-0.94%) ▼|SPG219.09-8.10 (-3.57%) ▼|T21.12+0.03 (+0.14%) ▲|TMO510.13-6.49 (-1.26%) ▼|TMUS180.14-4.59 (-2.48%) ▼|TSLA394.06-8.84 (-2.19%) ▼|TXN301.32+8.02 (+2.73%) ▲|UBER73.60-0.73 (-0.98%) ▼|UNH425.60-2.59 (-0.60%) ▼|UNP280.94-2.18 (-0.77%) ▼|UPS109.94-2.02 (-1.80%) ▼|USB61.00-1.89 (-3.01%) ▼|V347.53-4.67 (-1.33%) ▼|VZ42.45-0.14 (-0.33%) ▼|WFC85.56-1.62 (-1.86%) ▼|WMT113.10+1.56 (+1.40%) ▲|XOM141.13-0.56 (-0.40%) ▼|
22.2 C
New York
Thursday, July 9, 2026

Tag: development

newssourceFORcompanyinformationcontent1releasesmarket

Smart Women Invest: Why Amazon Stock Could Boost Your Portfolio This July

Hey lovely ladies, let’s dive into the world of Amazon and see if it’s a good time to grab some of those shiny stocks...

4TEEN4 Doses First Patient in Phase 1b/2a Trial of Procizumab, a Monoclonal Antibody Targeting the Biological Driver of Shock

Hennigsdorf/ Berlin, July 23, 2025 – 4TEEN4 Pharmaceuticals GmbH today announced that the first patient has been dosed in a Phase 1b/2a PROCARD1 clinical trial evaluating its monoclonal antibody, procizumab, in patients with shock caused primarily by cardiogenic events. Shock is a life-threatening condition characterized by a sudden breakdown in circulatory function due to end-stage disease or acute events, which often leads to organ failure. With only symptomatic treatment options available, shock is associated with a high mortality rate of over 50%. The Phase 1b/2a trial is designed to identify a target dose for procizumab in preparation for further clinical development. In addition, the trial will provide signals of efficacy. In a Phase 1 study in healthy volunteers, procizumab was well tolerated.

Algorithmica Reports 35% Return in First Fiscal Year, Driven by Machine Learning Trading Technology

LUGANO, Switzerland, July 23, 2025 /PRNewswire/ -- Algorithmica, a cutting-edge technology provider of proprietary machine learning systems built upon the principles of Artificial Intelligence,...

Guidehouse Research Explores Evolving Electric Vertical Takeoff and Landing Technology Market

eVTOLs are on the verge of full commercial manufacturing and approval BOULDER, Colo., July 23, 2025 /PRNewswire/ -- A new report from Guidehouse Research explores electric vertical takeoff...

VEON to Release 2Q25 Earnings Update on August 7, 2025


SEGULA Technologies strengthens its presence on the African continent by opening an office in South Africa

CAPE TOWN, South Africa, July 23, 2025 /PRNewswire/ -- SEGULA Technologies officially sets up in South Africa: by opening a design office in Cape...

SEGULA Technologies strengthens its presence on the African continent by opening an office in South Africa

CAPE TOWN, South Africa, July 23, 2025 /PRNewswire/ -- SEGULA Technologies officially sets up in South Africa: by opening a design office in Cape...

Getchell Gold Corp. Commences Drill Program at Fondaway Canyon, Nevada

VANCOUVER, BC, July 23, 2025 /CNW/ - Getchell Gold Corp. (CSE: GTCH) (OTCQB: GGLDF) (FWB: GGA1) ("Getchell" or the "Company") is pleased to announce...

Rakovina Therapeutics KT-5000AI Program Yields Potent ATR Inhibitor Hits in Early Screening

Compounds developed through collaboration with Variational AI show targeted activity 
Compounds developed through collaboration with Variational AI show targeted activity

Singapore-Based Innovative Biomedical Start-Up Achieves ‘Strategic Triumph’ to Conquer Chinese Med-Tech Market

NMPA grants Syntellix product approval for the world's most important future market with more than 1.4 billion people Syntellix' product approval for China...

Singapore-Based Innovative Biomedical Start-Up Achieves ‘Strategic Triumph’ to Conquer Chinese Med-Tech Market

NMPA grants Syntellix product approval for the world's most important future market with more than 1.4 billion people Syntellix' product approval for China...

NetDragon Achieves “A” Rating in Wind ESG Assessment, Demonstrating Strong Commitment to Sustainable Development Principles

HONG KONG, July 23, 2025 /PRNewswire/ -- NetDragon Websoft Holdings Limited ("NetDragon" or the "Company", Hong Kong Stock Code: 777), a global leader in building...

Intellistake Technologies Corp. Appoints Mario Casiraghi, Leading AI Digital Asset Ecosystem CFO at SingularityNET Foundation and CEO of Established $90M USD AUM Digital Asset...

Group CFO of SingularityNET Foundation since 2020, scaling the ecosystem from $40M USD market cap to multi-billion USD market cap $90M USD in digital...

Cytovation to Advance Development of CY-101 for Cancers Driven by Dysfunction of Wnt/β-catenin Signalling Under International Nonproprietary Name of Getacatetide

Bergen, Norway, July 23, 2025 – Cytovation ASA, a clinical stage oncology company focused on the development of its first-in-class bifunctional peptide CY-101, announces that the International Nonproprietary Names (INN) Expert Committee of the World Health Organization (WHO-INN) has approved "getacatetide" as the International Nonproprietary Name (INN) of CY-101.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsDevelopment

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers